Calidi Biotherapeutics completed its reverse merger with First Light Acquisition Group, a blank-check vehicle that raised $100 million in its February 2021 IPO. The transaction moves Calidi's EncephaVir platform—engineered neural stem cells that target solid tumors—from private development into public equity markets. Trading begins under ticker CLDI. First Light shareholders approved the combination in a special meeting; redemption rates and pro forma cash on the balance sheet were not disclosed in initial filings.
Calidi has been in clinical trials since 2019, testing its lead candidate against recurrent high-grade glioma. The stem cells are designed to migrate through brain tissue, delivering oncolytic viruses directly to tumor sites while avoiding healthy neurons. The company reported interim Phase I data in late 2023 showing manageable safety profiles in 18 patients, though efficacy endpoints remain immature. The merger provides runway to advance into Phase II and to file an IND for a second indication in metastatic breast cancer to the brain, expected in the second half of 2025.
The timing matters because allogeneic cell therapy financing collapsed after 2021. Venture rounds for off-the-shelf platforms fell 62% by deal count from 2021 to 2023, per PitchBook. CAR-T dominance by Gilead and Bristol Myers narrowed allocator appetite for earlier-stage competitors without autologous proof-of-concept. Calidi's SPAC route reflects that drought: traditional crossover funds that bridged biopharma Series C rounds into IPOs largely disappeared. First Light, a vehicle sponsored by serial SPAC promoter Emmett McCann, had been seeking targets for over two years. The deal rescues both parties from extension votes and redemption spirals.
Operators should track two catalysts. First, Calidi's Phase I final data readout is scheduled for mid-2025, with overall survival and progression-free survival endpoints that will set valuation benchmarks against autologous competitors. Second, the company must file an S-1 or 8-K detailing pro forma capitalization, insider lock-ups, and earn-out structures within 30 days of closing. Those filings will reveal dilution risk and whether pipe investors took discounts steep enough to pressure the float.
The merger adds another distressed biotech to a crowded field of post-SPAC survivors trading below $3 per share. Calidi enters with clinical momentum but no revenue, no partnerships, and a burn rate that will require either partnership economics or a follow-on offering by the fourth quarter of 2025.